Business
Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum
Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum Mont-Saint-Guibert, Belgium – May 20, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today participated in an exclusive afternoon organized at LégiaPark, the life sciences innovati
About this update from Nyxoah Sa
[{"type":"image","alt":"Nyxoah","displaySize":"","headline":null,"caption":"Nyxoah","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/f090b0134f1a96c88516737ccd77cad1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FbfhsHKC3cqGVKfmi0y0gQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Mg--/https://media.zenfs.com/en/globenewswire.com/f090b0134f1a96c88516737ccd77cad1","width":300,"height":116},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/FbfhsHKC3cqGVKfmi0y0gQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Mg--/https://media.zenfs.com/en/globenewswire.com/f090b0134f1a96c88516737ccd77cad1","width":300,"height":116}},"lazy":false},{"type":"text","content":"Nyxoah Welcomes the Flemish Investors Federation (VFB) at LégiaPark following Q1 2026 Results and U.S. Commercial Momentum","length":122,"tagName":"p"},{"type":"text","content":"Mont-Saint-Guibert, Belgium – May 20, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today participated in an exclusive afternoon organized at LégiaPark, the life sciences innovation campus in Liège, Belgium. The event, which took place at LégiaPark alongside neighbouring listed company Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), brought together up to 40 investors and members of the press for a comprehensive update on both companies.","length":644,"tagName":"p"},{"type":"text","content":"Olivier Taelman, Chief Executive Officer of Nyxoah, walked attendees through the strong commercial progress of the Genio® system in the United States, less than a year after FDA approval in August 2025. He also revisited Nyxoah's recently announced LégiaPark investment, a large manufacturing facility designed to scale industrial capacity in line with the Company's growth ambitions.","length":392,"tagName":"p"},{"type":"text","content":"Stijn Van Rompay, Chief Executive Officer of Hyloris, then presented Hyloris' strategy, broad pipeline of innovative drug candidates and its 2025 highlights, before guiding attendees through the company's R&D facilities and illustrating the depth of the life sciences ecosystem developing on the LégiaPark campu...